Redcare Pharmacy raises 2026 guidance. Redcare Pharmacy stock gains 6.69 percent.

Published on 10/07/2026 at 14:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

German Rx revenue outlook reaches EUR 730 million to EUR 760 million. Redcare Pharmacy stock costs EUR 72.53 on October 7, 2026, versus EUR 67.98.

Geometrisches Bauhaus-Poster mit Pillenformen, Kreuzsymbol und dem Wort PHARMA — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, gestaltet Bauhaus-Poster mit Pillenformen, Kreuzsymbol und Schriftzug PHARMA, Illustration mit AI erstellt.

Redcare Pharmacy stock (ISIN NL0012044747) was trading at EUR 72.53 at Lang & Schwarz on October 7, 2026 at 2:33 p.m. CEST, up 6.69 percent versus the prior close of EUR 67.98. The company raised its full-year 2026 revenue outlook on September 28, 2026, with German prescription revenue now expected at EUR 730 million to EUR 760 million.

Rx outlook moves higher

According to Redcare Pharmacy on September 28, 2026, the German Rx revenue range increased from EUR 680 million to EUR 720 million to EUR 730 million to EUR 760 million. The company also lifted full-year 2026 total revenue growth guidance from 15 percent to 17 percent to 16 percent to 18 percent.

The upgrade was the second guidance increase of 2026. Preliminary German Rx revenue grew 51 percent year over year in September and 56 percent in the third quarter of 2026, while the adjusted EBITDA margin guidance remained at 2.5 percent to 3.0 percent.

Quarterly growth supports upgrade

mwb research reported on September 29, 2026, that Redcare Pharmacy generated EUR 853.5 million of sales in the second quarter of 2026, versus EUR 709.0 million in the second quarter of 2025, a 20.4 percent increase. Adjusted EBITDA rose to EUR 29.1 million from EUR 16.6 million, while the adjusted EBITDA margin increased from 2.3 percent to 3.4 percent.

mwb research maintained its BUY rating and EUR 95.00 price target on September 29, 2026. Against the Lang & Schwarz price of EUR 72.53, that target is 30.99 percent higher, although the research also highlights the tougher comparison base created by the previous year's prescription bonus.

Stock remains below yearly high

Redcare Pharmacy had a market capitalization of EUR 1.5 billion on October 7, 2026. Its 52-week range was EUR 30.20 to EUR 90.05, leaving the Lang & Schwarz price 19.46 percent below the high and 140.17 percent above the low.

Redcare Pharmacy is scheduled to publish its interim statement for the third quarter of 2026 on October 29, 2026, according to Redcare Pharmacy. The next report will test whether German Rx growth can sustain the higher full-year outlook.

The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.